Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
22.62
Price to sales ratio
2.19
Dividends per share
0.82
Dividend yield %
4.8

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
238
CL
Colgate-Palmolive Company Common Stock
90.97 USD-1.18%+1.12%+0.03%+9.30%72.52 B USD
395
EL
Estee Lauder Companies, Inc. Common Stock
106.22 USD+1.13%+10.30%+28.27%+16.53%38.43 B USD
403
KMB
Kimberly-Clark Corporation - Common Stock
109.98 USD-0.33%+1.27%-0.79%+2.31%36.58 B USD
536
CHD
Church & Dwight Company, Inc. Common Stock
102.39 USD-0.46%+5.09%+4.38%+19.21%24.29 B USD

Frequently asked questions about Kenvue Inc.

What is the Kenvue Inc. stock price today?

The current price of Kenvue Inc. (KVUE) is 19.21. Over the past 24 hours, the stock has changed by -0.05%. Follow the KVUE chart for real-time price dynamics.

What is the stock ticker of Kenvue Inc.?

Kenvue Inc. trades under the ticker KVUE. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Kenvue Inc. stock going up?

KVUE has changed by +1.11% over the last week, -1.64% over the last month, and +27.39% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Kenvue Inc.?

Kenvue Inc. currently has a market capitalization of 36.9 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

Does Kenvue Inc. release financial reports?

Yes. You can track Kenvue Inc. financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What were Kenvue Inc. earnings last quarter?

Last quarter, Kenvue Inc. reported earnings of 0.17 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Kenvue Inc. revenue for the last quarter?

Kenvue Inc. reported quarterly revenue of 3.78 B. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Kenvue Inc. net income for the last quarter?

Kenvue Inc. reported net income of 330 M for the last quarter. The previous quarter showed 398 M, which means net income changed by -17.09%.

Does Kenvue Inc. pay dividends?

Kenvue Inc. paid a dividend per share of 0.82. The current dividend yield is 4.8%. Dividend data can help income-focused investors evaluate the stock.

How many employees does Kenvue Inc. have?

As of the latest available data, Kenvue Inc. has 22 K employees. Workforce size can provide additional context about the company's scale and operations.

What is Kenvue Inc. EBITDA?

Kenvue Inc. EBITDA is -6 M, and its EBITDA margin is -0.16%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Kenvue Inc. stock?

You can buy Kenvue Inc. (KVUE) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Kenvue Inc. stock?

Investing in Kenvue Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the KVUE chart and related analysis on metatrader.com as part of your research.

Kenvue Inc. Common Stock

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

News